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Introduction {#onco12112-sec-0001}
============

Breast cancer is one of the most common malignancies in females. GLOBOCAN data from 2012 show that in China, morbidity and mortality associated with breast cancer have increased rapidly \[[1](#onco12112-bib-0001){ref-type="ref"}\]. Some studies have shown that genetic predisposition as a pathogenic factor, together with hereditary factors, plays an important role in such heterogeneous disease \[[2](#onco12112-bib-0002){ref-type="ref"}\]. Molecular subtypes are well accepted based on genomic and histological features. Breast cancer can be basically divided into four subtypes (Luminal A, Luminal B, human epidermal growth receptor 2 \[HER2\]‐amplified, and basal‐like) \[[3](#onco12112-bib-0003){ref-type="ref"}\]. These subtypes are significantly different in biological features, which implicate treatment and prognostic evaluation \[[4](#onco12112-bib-0004){ref-type="ref"}\]. Although molecular subtypes have been routinely used in clinical work, especially for matching the appropriate medicine to a patient \[[5](#onco12112-bib-0005){ref-type="ref"}\], the comprehensive genetic understanding of different molecular subtypes is still not clear. To date, genome‐wide association studies (GWAS) have identified more than 90 susceptibility loci associated with breast cancer \[[6](#onco12112-bib-0006){ref-type="ref"}\], most of which expand the genetic features and contribute to pathogenic study. However, few loci have been further studied according to molecular subtype \[[7](#onco12112-bib-0007){ref-type="ref"}\], \[[8](#onco12112-bib-0008){ref-type="ref"}\]. In our previous study, several specific molecular subtype‐associated loci were confirmed; for example, *3p24.1/TGFBR2* (rs12493607) was associated with HER2‐amplified breast cancer, and *16q12.2/FTO* (rs11075995) was associated with basal‐like breast cancer \[[9](#onco12112-bib-0009){ref-type="ref"}\], \[[10](#onco12112-bib-0010){ref-type="ref"}\].

Some novel susceptibility loci/genes in Europeans have been identified in recent years \[[11](#onco12112-bib-0011){ref-type="ref"}\], \[[12](#onco12112-bib-0012){ref-type="ref"}\], \[[13](#onco12112-bib-0013){ref-type="ref"}\], \[[14](#onco12112-bib-0014){ref-type="ref"}\]. The susceptibility of these loci in non‐European populations is still unknown and is of great interest \[[15](#onco12112-bib-0015){ref-type="ref"}\]. We have validated these loci and confirmed three loci in Chinese Han women: *5q11.2, 5q14.3*, and *10q26.1* \[16\]. Furthermore, we also studied these loci according to molecular subtype using a stratification analysis.

Materials and Methods {#onco12112-sec-0002}
=====================

Subjects {#onco12112-sec-0003}
--------

A total of 3,036 patients suffering from breast cancer (2,935 samples matched molecular subtypes) and 3,036 healthy controls (female only) were recruited through collaborations with Hospital No. 1 and Hospital No. 2, Anhui Medical University, in the province of Anhui. The basic breast cancer molecular characteristics are shown in Table [1](#onco12112-tbl-0001){ref-type="table"}. The estrogen receptor (ER) status, progesterone receptor (PR) status, and HER2 status were evaluated by examining the breast tissue by biopsy or cytology and immunohistochemical analysis. The diagnosis of each case was confirmed by at least two oncologists. All of the Chinese controls were clinically confirmed to be free of breast cancer, other neoplastic diseases, systemic disorders, or a family history of neoplastic diseases (including first‐, second‐, and third‐degree relatives). Uniform criteria were used for the recruitment of patients and controls. The same questionnaire was used to collect clinical and demographic information from each participant. After written informed consent was obtained, peripheral blood was collected from each participant. The study was approved by the Institutional Ethical Committee of each hospital and was conducted in accordance with the Declaration of Helsinki.

###### The basic breast cancer characteristics
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2,935 samples matched molecular subtypes.

Single Nucleotide Polymorphism Selection {#onco12112-sec-0004}
----------------------------------------

We choose 23 single nucleotide polymorphisms (SNPs) that passed the quality control test in our previous study \[[16](#onco12112-bib-0016){ref-type="ref"}\].

Stratification Analysis {#onco12112-sec-0005}
-----------------------

For stratification analysis, an association study was performed between selected SNPs and different cohorts in molecular subtypes.

Statistical Analysis {#onco12112-sec-0006}
--------------------

The association between the SNPs and breast cancer susceptibility was assessed using logistic regression, adjusting for age. The strength of association was estimated by calculating the odds ratio (OR) with a 95% confidence interval (CI). The Hardy‐Weinberg equilibrium was assessed using the chi‐square test. All of the statistical analyses were performed using SPSS 13.0 (IBM, Armonk, NY, <https://www.ibm.com>) and Plink 1.07 software. Conservatively accounting for the multiple comparisons by Bonferroni correction, the threshold for statistical significance was *p* \< 2.17 × 10^−3^ (.05/23).

Results {#onco12112-sec-0007}
=======

Through a stratification analysis, *5q11.2/MAP3K1* (rs16886034, *p* = 1.06 × 10^−3^, OR = 1.31; rs16886364, *p* = 5.87 × 10^−4^, OR = 1.31; rs16886397, *p* = 2.73 × 10^−4^, OR = 1.33; rs1017226, *p* = 3.75 × 10^−4^, OR = 1.32; rs16886448, *p* = 1.93 × 10^−4^, OR = 1.34) and *7q32.3/LINC‐PINT* (rs4593472, *p* = 1.10 × 10^−3^, OR = 0.78) were associated with Luminal A, and *10q26.1/FGFR2* (rs35054928, *p* = 2.01 × 10^−6^, OR = 1.27) was associated with Luminal B (Table [2](#onco12112-tbl-0002){ref-type="table"}).

###### Breast cancer‐specific molecular subtype‐associated susceptibility loci in Chinese Han women
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Minor allele/Major allele.

Minor allele frequency.

Abbreviations: CHR, chromosome; CI, confidence interval; MAF, major allele frequency; OR, odds ratio; SNP, single nucleotide polymorphisms.

Discussion {#onco12112-sec-0008}
==========

In our further association study, we confirmed some loci related to specific molecular subtypes in Chinese Han women. *5q11.2/MAP3K1* was first confirmed as a susceptibility gene for Chinese Han women, specifically in Luminal A breast cancer. *7q32.3/LINC-PINT* was first confirmed as a susceptibility loci/gene for Luminal A breast cancer. *10q26.1/FGFR2* was previously confirmed as a susceptibility gene for Luminal B breast cancer \[[17](#onco12112-bib-0017){ref-type="ref"}\], \[[18](#onco12112-bib-0018){ref-type="ref"}\].

rs16886034, rs16886364, rs16886397, rs1017226, and rs16886448 are in the mitogen‐activated protein kinase kinase kinase 1 (*MAP3K1*) gene, which is located on chromosome *5q11.2* and encodes a serine/threonine kinase that is involved in the mitogen‐activated protein kinase (MAPK) signaling pathway and is responsible for the transcriptional regulation of important cancer genes, including c‐Myc, c‐Elk1, c‐Jun, and c‐Fos \[[19](#onco12112-bib-0019){ref-type="ref"}\], \[[20](#onco12112-bib-0020){ref-type="ref"}\]. MAPK signal transduction is a critical pathway for cellular regulation and can be stimulated by a wide variety of exposures, including estrogen, in a variety of cell types \[[21](#onco12112-bib-0021){ref-type="ref"}\]. The *MAP3K1* gene has been identified in many GWAS of breast cancer \[[22](#onco12112-bib-0022){ref-type="ref"}\], \[[23](#onco12112-bib-0023){ref-type="ref"}\], \[[24](#onco12112-bib-0024){ref-type="ref"}\], \[[25](#onco12112-bib-0025){ref-type="ref"}\], and a number of studies have investigated the relationship between *MAP3K1* and breast cancer subtypes; the results were inconsistent in different breast cancer subtypes. MAP3K1 expression is upregulated in the Luminal A subtype and downregulated in the Luminal B, HER2‐amplified, and basal‐like subtypes \[[26](#onco12112-bib-0026){ref-type="ref"}\], \[[27](#onco12112-bib-0027){ref-type="ref"}\]. A somatic mutation study of breast‐invasive carcinoma in the context of mRNA expression subtypes revealed that *MAP3K1* alterations were enriched in the Luminal A subtype \[[28](#onco12112-bib-0028){ref-type="ref"}\].

rs4593472 was in *LINC‐PINT* on Chromosome *7q32.3*. *LINC‐PINT* is a p53‐induced long intergenic non‐protein‐coding RNA located in a 375 kb region between *MKLN1* and *KLF14*. *KLF14* is a member of the Kruppel‐like family of transcription factors, which are tumor suppressors \[[29](#onco12112-bib-0029){ref-type="ref"}\]. Michailidou reported that this SNP was associated with ER‐positive breast cancer \[[30](#onco12112-bib-0030){ref-type="ref"}\].

The SNP rs35054928 is located in the intronic region of the fibroblast growth factor receptor 2 (*FGFR2*) gene. *FGFR2* encodes fibroblast growth factor receptor type 2, which is a receptor tyrosine kinase that plays a critical role in the growth signaling pathway and is involved in the growth and differentiation of cells in various tissues among many tumors \[[31](#onco12112-bib-0031){ref-type="ref"}\], \[[32](#onco12112-bib-0032){ref-type="ref"}\]. Intron 2 of *FGFR2* contains putative transcription factor binding sites, increases Oct‐1/Runx2 and C/EBPb transcription factor binding, which increases *FGFR2* expression \[[33](#onco12112-bib-0033){ref-type="ref"}\], and causes poor overall survival and disease‐free survival \[[34](#onco12112-bib-0034){ref-type="ref"}\], \[[35](#onco12112-bib-0035){ref-type="ref"}\]. The association between the *FGFR2* gene and breast cancer appears to be stronger for ER‐positive and PR‐positive tumors than for ER‐negative or PR‐negative tumors, which suggests a sex hormone‐dependent role of the *FGFR2* gene in breast cancer \[[36](#onco12112-bib-0036){ref-type="ref"}\], \[[37](#onco12112-bib-0037){ref-type="ref"}\], \[[38](#onco12112-bib-0038){ref-type="ref"}\]. *FGFR2* was associated with Luminal B, as reported by O\'Brien et al. \[[17](#onco12112-bib-0017){ref-type="ref"}\] and Liang et al. \[[18](#onco12112-bib-0018){ref-type="ref"}\], similar to that observed in our study.

Luminal A and Luminal B breast cancers are also ER‐positive breast cancers. Luminal tumors represent around two thirds of all breast cancers. Luminal breast cancer is a highly heterogeneous disease comprising different histologies, gene expression profiles, and mutational patterns, with very varied clinical courses and responses to systemic treatment \[[39](#onco12112-bib-0039){ref-type="ref"}\], \[[40](#onco12112-bib-0040){ref-type="ref"}\]. Due to the heterogeneity of breast cancer, it is necessary to define suitable patient cohorts and predictive biomarkers for a personalized therapy with a high therapeutic index \[[41](#onco12112-bib-0041){ref-type="ref"}\]. Some next‐generation sequencing studies show Luminal A tumors frequently exhibit abrogation of stress‐induced apoptotic kinase c‐Jun NH2‐terminal kinase (JNK) signaling and loss‐of‐function mutations in the *MAP3K1* genes; this abrogation has been associated with resistance to chemotherapy compared with patients with normal JNK signaling \[[42](#onco12112-bib-0042){ref-type="ref"}\]. That could explain why Luminal A tumors are not sensitive to chemotherapy \[[43](#onco12112-bib-0043){ref-type="ref"}\], \[[44](#onco12112-bib-0044){ref-type="ref"}\]. Fibroblast growth factor receptor (FGFR) signaling through FGF ligand‐dependent or ‐independent activation has been implicated in oncogenesis, angiogenesis, and treatment resistance in various tumor types \[[45](#onco12112-bib-0045){ref-type="ref"}\]. Approaches to targeting FGFR in various tumor types include tyrosine kinase inhibitors (TKIs), monoclonal FGFR antibodies, and FGF‐trapping molecules, with TKIs being more clinically advanced. A phase II clinical trial assessing dovitinib, a nonselective FGFR TKI, showed activity in the subgroup of patients with ER‐positive/HER2‐negative breast cancer \[[44](#onco12112-bib-0044){ref-type="ref"}\], \[[46](#onco12112-bib-0046){ref-type="ref"}\]. One type of Luminal B is ER‐positive and/or PR positive, HER2‐negative, with ki67 ≥14% \[[40](#onco12112-bib-0040){ref-type="ref"}\]. The association between Luminal B subtype and *FGFR2* gene in Chinese Han implicate a potential drug indication of TKI in Chinese Luminal B breast cancer patients. However, it needs more clinical trial to confirm.

Conclusion {#onco12112-sec-0009}
==========

In summary, we confirmed that *5q11.2/MAP3K1* and *7q32.3/LINC‐PINT* were associated with Luminal A, and *10q26.1/FGFR2* was associated with Luminal B. In our study, breast cancer‐specific molecular subtype‐associated susceptibility loci were confirmed in Chinese Han women, which contributes to a better genetic understanding of breast cancer in different molecular subtypes. These specific molecular subtype‐associated loci are potentially meaningful for guiding clinical evaluation and therapy.
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